Utilizing the cytoplasmic tail of Transforming Growth Factor Receptor Type II (TGFb RII) as bait in a yeast two hybrid system, we have identi®ed human cyclin B2 as a direct physical partner of TGFb RII. Analysis of deletion mutants of glutathione-S-transferase (GST)-cyclin B2 mapped its binding domain for TGFb RII to the C-terminal and revealed a negative regulatory region immediately upstream of the cyclin box. Using recombinant proteins, Cdc2 was demonstrated to indirectly interact with TGFb RII via cyclin B2. This interaction was reproduced in THP-1 monocytic cells, where TGFb treatment markedly enhanced the ability of cyclin B2 and, correspondingly, Cdc2 from TGFb-treated THP-l cells, to bind the GST-TGFb RII fusion protein. More importantly, TGFb RII co-precipitated with cyclin B2 in TGFb-treated THP-1 cells. TGFb treatment also caused threonine phosphorylation of Cdc2 in the TGFb RIIcyclin B2-Cdc2 complex in THP1 cells, in parallel with down regulation of Cdc2 function as measured by histone H1 kinase activity. Cyclin B1 had the same capacity to bind TGFb RII and mediate indirect Cdc2 binding. These results suggest an alternative mechanism that cell cycle arrest in the G1/S phase caused by TGFb may, in part, be due to inactivation of cyclin B/Cdc2 kinase, which is needed for entry into the G2/M phase.
Utilizing the cytoplasmic tail of Transforming Growth Factor Receptor Type II (TGFb RII) as bait in a yeast two hybrid system, we have identi®ed human cyclin B2 as a direct physical partner of TGFb RII. Analysis of deletion mutants of glutathione-S-transferase (GST)-cyclin B2 mapped its binding domain for TGFb RII to the C-terminal and revealed a negative regulatory region immediately upstream of the cyclin box. Using recombinant proteins, Cdc2 was demonstrated to indirectly interact with TGFb RII via cyclin B2. This interaction was reproduced in THP-1 monocytic cells, where TGFb treatment markedly enhanced the ability of cyclin B2 and, correspondingly, Cdc2 from TGFb-treated THP-l cells, to bind the GST-TGFb RII fusion protein. More importantly, TGFb RII co-precipitated with cyclin B2 in TGFb-treated THP-1 cells. TGFb treatment also caused threonine phosphorylation of Cdc2 in the TGFb RIIcyclin B2-Cdc2 complex in THP1 cells, in parallel with down regulation of Cdc2 function as measured by histone H1 kinase activity. Cyclin B1 had the same capacity to bind TGFb RII and mediate indirect Cdc2 binding. These results suggest an alternative mechanism that cell cycle arrest in the G1/S phase caused by TGFb may, in part, be due to inactivation of cyclin B/Cdc2 kinase, which is needed for entry into the G2/M phase.
Keywords: transforming growth factor receptor; cyclin B; cdc-2; cell cycle control Transforming growth factor b (TGFb) is a potent regulator of cell growth and dierentiation. It controls the cell fate by regulating the expression of cyclindependent kinases (Cdk), dierentiation factors, and tumor suppressor gene products. TGFb inhibits Mv1Lu lung epithelial cell proliferation by inducing G1 arrest through the inhibition of cyclin D/Cdk4/6, cyclin E/Cdk2, or cyclin A/Cdk2 kinases. TGFb induces down-modulation of Cdk4 synthesis which further leads to inhibition of Cdk2 activation, thus resulting in cell cycle arrest in responsive cells. Constitutive Cdk4 synthesis in these cells leads to TGFb resistance (Ewen et al., 1993; Ko et al., 1993; Satterwhite et al., 1994) . TGFb inhibition of cell proliferation is via the induction and activation of the tumor suppressor gene products, p15 and p27 ,that coordinately inhibit Cdk function (Toyoshima and Hunter, 1994; Blain et al., 1997; Reynisdottir and Massague, 1997) . In Mv1Lu lung epithelial cells, TGFb could prevent retinoblastoma (Rb) protein phosphorylation during G1 phase, and hypophosporylated forms of Rb suppress progression into the S phase (Laiho et al., 1990; Goodrich et al., 1991) . By contrast, TGFb stimulates growth in established cell lines of mesenchymal origin and, in C3H mouse ®broblasts paradoxically, it induces cell cycling via activation of cyclin E-Cdk2 kinase (Ravitz et al., 1995) .
The eect of TGFb is transmitted via a heteromeric complex of type I and type II transmembrane serine/ threonine kinase receptors. The type II receptor (RII) binds TGFb and is constitutively phosphorylated, while TGFb RI cannot bind its ligand without TGFb RII, suggesting that it is probably a downstream substrate of TGFb RII (Wrana et al., 1994; Chen et al., 1995; Chen and Derynck, 1994) . However, the signal pathways downstream of these receptors are not completely understood. Several ®ndings suggest that divergent signaling pathways could be mediated with either type I or type II receptor. Speci®c interaction of TGFb RI with the immunophilin FKBP-12 and p21 RAS farnesyltransferase a subunit has been described, suggesting that regulation of the activation of G proteins is one of the mechanisms involved in TGFbmediated growth inhibitory and dierentiative pathways (Wang et al., 1994; Chen et al., 1997) . MADR2 is another intermediate protein that directly interacts with TGFb RI, and its phosphorylation is required for nuclear accumulation and initiation of signaling (Macias-Silva et al., 1996) . Smad proteins as TGFb signal transducers via TGFb RI have also been reported Kretzschmar et al., 1997; Liu et al., 1997) .
TGFb RII has also been implicated in TGFbmediated growth arrest, but its mechanism is unclear (Chen et al., 1993 Derynck, 1994 . A WDdomain-containing protein, TRIP-1, which speci®cally associates with TGFb RII in a kinase-dependent manner has been identi®ed. TRIP-1 does not interact with the type II activin receptor or TGFb RI, but is associated with the heterometric TGFb receptor complex (Chen et al., 1995) . Other than TRIP, little is known of signal events directly associated with TGFb RII. With this in mind, we utilized a yeast twohybrid system to identify the direct downstream events from TGFb RII that might be responsible for its eect on cell growth.
The cytoplasmic domain of TGFb RII (RIIC) was used as`bait' to screen (Harper et al., 1993; Wang et al., 1994 , Chen et al., 1995 a cDNA library from EBV transformed human B cells expressed in the pACT vector (Clontech), to isolate cDNAs for TGFb RII- (Lin et al., 1992) was ampli®ed by polymerase chain reaction with the following primers: 5'-TACGAATTCAACCGGCAGCAGAAGCTGAGTTCAACCTGGG-3' and 5'-GTGGATCCGG-CAGCCTCTTTGGACATGCCCAGCCTGC-3'. The ampli®ed DNA was digested with EcoRI and BamHI and inserted into the EcoRI ± BamHI site at the 3' end of the GAL4 DNA binding domain in pGBT9 (Clontech). This construct was used for two-hybrid screening (Chomczynski and Sacchi, 1987; Guarente, 1993; Harper et al., 1993) of an EBV-transformed human peripheral blood lymphocyte cDNA library fused with the GAL4 activation domain in the pACT vector (Clontech). The TGFb RII-DNA binding domain plasmid and this B cell library were cotransformed into a yeast host strain (HF7c), and cotransformants were selected on the appropriate synthetic minimal dropout medium. Cotransformant colonies were assayed (on ®lters) for b-galactosidase activity. To avoid false positive results, all the control plasmids provided by Clontech were included in the screening procedure. Resulting positive clones were mated with SFY526 strains containing the unrelated proteins, lamin C and p53, fused to the GAL4 DNAbinding domain and tested for b-galactosidase activity to eliminate the possibility of nonspeci®c binding. Identical amino acids among the various cyclin B species are indicated by a line (7), conservative substitutions by a dot (.). The boxed region indicates the highly conserved amino acid region among cyclins, the`cyclin box'. Western blot analysis of cyclin B2 protein expression in PBMC. Whole cell lysates prepared from PBMC, stimulated with 1 mg/ml of phytohemaglutinnin (PHA) for 0 ± 48 h at 378C, were probed with anti-cyclin B2 (top panel), stripped, and reprobed with anti-ERK1 to check for equal loading interacting proteins. One of the 288 positive clones that scored for speci®c interaction with TGFb RIIC contained a partial cDNA of 870 bases. Sequencing and homology search through GENBANK databases revealed it to be extensively homologous to the cloned cyclins, showing 94.7%, 91.1% and 60.2% homology to hamster cyclin B2, mouse cyclin B2 and human cyclin B1, respectively ( Figure 1a) . Upon obtaining the cDNA as well as the sequence of human cyclin B2 from Dr Steve Reed, Scripps Research Institute (La Jolla, CA, USA) we found that our isolated clone was identical to human cyclin B2 in a truncated form (cyclin B2T). It contained a complete cyclin box and Cterminal, lacking only the ®rst 151 amino acids ( Figure  1b ). Cyclin B1 is universally required for cell cycle entry into mitosis, but the participation of cyclin B2 is unclear. We therefore ®rst analysed its distribution in dividing cells and detected a 1.7 kb cyclin B2 mRNA in Figure 2 Interaction of cyclin B and Cdc2 with TGFb RII. (a) Detection of GST-cyclin B1 with anti-B1. The full length cyclin B2 (kindly provided by Dr Steven I Reed, Scripps Research Institute, La Jolla, CA, USA) and its deletion mutants were subcloned into various restriction sites of GST vectors depending on the reading frame (Pharmacia) by PCR ampli®cation. The cyclin B2T selected from the pACT EBV-transformed B cell cDNA library was subcloned into the XhoI site of pGEX-5X-2. To generate GST-cyclin B1, the full length cyclin B1 was digested from its pGEM4 vector (kindly provided by Dr Tony Hunter, The Salk Institute for Biological Studies, San Diego, CA, USA) with ScaI and NcoI restriction enzymes and subcloned into the SmaI site of pGEX-5X-1. The TGFb RII and its kinase-de®cient form (KR) was provided by Dr Xiao Feng Wang, Duke University Medical Center (Durham, NC, USA). The cytoplasmic regions of wild type and kinase-de®cient of TGFb RII were PCR ampli®ed and subcloned into pGEX-5X-1 at the EcoI and XhoI sites (GST-RII and GSTRII (KR)). The Cdc2 cDNA (kindly provided by Dr Tony Hunter) was also ampli®ed by PCR and subcloned into the EcoRI and XhoI sites of pGEX-5X-1(GST-Cdc2). For the induction of GST fusion proteins in bacteria, overnight cultures of transformed DH5a at the middle log phase (A 600 of 0.6 ± 0.8) of growth were adjusted to 100 mM isopropyl-1-thio-b-D-galactoside and incubated for 3 h at 308C to induce the synthesis of recombinant proteins. The cells were harvested by centrifugation and resuspended in 16phosphate buer saline (PBS). All subsequent steps were carried out at 48C. The cells were lysed by sonication and the lysates were centrifuged at 18 000 g for 45 min. The supernatant was then ®ltered through a 0.45 mM ®lter (Millipore) and applied onto GSH-Sepharose anity matrix. The matrix was washed with 10 volumes of PBS. The GST fusion proteins can be maintained on the matrix and stored at 7708C. GST (lane 1), GST-cyclin B1 (lane 2), and GST-cyclin B2T (lane 3) were released from gluthione-Sepharose by boiling in SDS sample buer, separated in a 10% SDS ± PAGE gel, transferred to a nitrocellulose membrane and visualized by Western blotting with anti-cyclin B MoAb (UBI). (b) Detection of GST-cyclin B2 with anti-cyclin B2. The same aliquots as (a) were blotted with the anity-puri®ed rabbit anti-cyclin B2 prepared against peptide 152 ± 164 of cyclin B2. (c) Interaction of cyclin B2T with the cytoplasmic domain of TGFb RII in vitro. The anity puri®ed GST-B2T was cleaved at the fusion site of GST and cyclin B2T by 10 units/mg of thrombin for 16 h at 258C according to the manufacturer's instructions (Pharmacia). The recombinant cyclin B2T was puri®ed twice with glutathione sepharose 4B to remove any contaminating GST and then applied onto GST (lane 1), GST-RII (lane 4), or GST-RII (KR) (lane 5). GST-RII (lane 2) and GST-RII (KR) (lane 3) alone were used as negative controls. One ®fth of recombinant cyclin B2T was loaded on the SDS ± PAGE as a positive control (lane 6). After washing three times, the absorbed proteins were separated by SDS ± PAGE and blotted with anti-cyclin B2. (d) Schematic drawing of the deletion mutations of cyclin B2 and summary of their interaction with TGFb RII. The`cyclin box' region is within the box. These data represent one of three experiments which generated similar results. (e) Indirect interaction of TGFb RII with Cdc2 mediated by cyclin B2. GST-free cyclin B2 or B2T was mixed with GST-RII at room temperature for 30 min. After extensive washing, GST-free Cdc2 was added under the same conditions. The absorbed proteins were separated by SDS ± PAGE and blotted with anti-Cdc2 all proliferating cell lines tested, but not in resting peripheral blood mononuclear cells (PBMC) ( Figure  1c) . However, upon activation with a mitogen, phytohemaglutinnin, PBMC rapidly synthesized cyclin B2 within 4 h (Figure 1d ). Equal loading of proteins in the lanes was checked by demonstrating comparable levels of mitogen-activated protein kinase/Erk1.
In contrast to nuclear localization of cyclin D, E, and A, cyclin B is uniformly distributed throughout the cell, including the cytoplasm (Jackman et al., 1995) . This oers the possibility for the direct interaction of cyclin B2 with a surface receptor like TGFb RII. Therefore, glutathione-S-transferase fusion proteins of cyclin B1 (GST-B1) and B2 (GST-B2) were prepared for direct binding to recombinant TGFb RII. Commercial anti-cyclin B monoclonal antibody (MoAb), only recognized GST-B1 but not GST-B2T (Figure 2a) . To generate an anti-cyclin B2 speci®c antibody, peptide 152 ± 164 of cyclin B2, which is the ®rst 12 amino acids of cyclin B2T with no homology to human cyclin B1, was used to immunize three rabbits (AnaSpec, San Jose, CA, USA). This anity-puri®ed polyclonal antibody only speci®cally reacted with GST-B2T, but not with GST-B1 (Figure 2b ). Preimmune rabbit serum and murine isotype control Ig did not react with GST-B2T and GST-B1 (data not shown). Western blot analysis with anti-B2 indicated that B2T, puri®ed from GST-B2T by thrombin cleavage, interacted speci®cally with a GST-RII fusion protein (Figure 2c ), but not with GST alone. A kinasede®cient RII (K277R) (Wrana et al., 1994) was equally capable of cyclin B2 binding, indicating this interaction to be independent of RII kinase function (Figure 2c ). To dissect out the binding domain of cyclin B2 for TGFb RII, full length cyclin B2 and its deletion mutants were constructed as GST-fusion proteins and cleaved with thrombin for binding to the GST-cytoplasmic domain of TGFb RII fusion protein (GST-RII). In comparison to cyclin B2T, the complete protein encoded by full-length cyclin B2 bound RII weakly (Figure 2d ). Sequential deletion from the 5'-end indicated that deletion of up to 89 amino acids caused no alteration in the weak binding of cyclin B2 with GST-RII, but a deletion of the ®rst 151 amino acids (i.e. B2T) markedly enhanced it. Thus, a negative regulatory role existed between 89 ± 151 amino acids ahead of the cyclin box. Deletion of the last 134 amino acids of the C-terminal completely abolished RII binding, isolating the binding site to this location.
Based on the known function of cyclin B to form a complex with Cdc2 for proper kinase activity (Pines and Hunter, 1989) , the indirect association of RII with Cdc2 via cyclin B2 was next examined. Recombinant puri®ed Cdc2 from bacterial GST fusion protein did not bind to GST-RII by itself, but did bind GST-RII in the presence of cyclin B2 or cyclin B2T (Figure 2e) . Binding of Cdc2 to GST-RII was signi®cantly greater with B2T than full-length B2, which is in line with the enhanced binding of the truncated cyclin B2 to RII seen in Figure 2d . These results suggest that the interaction of RII and cyclin B2 mediates the membrane localization of Cdc2.
We next evaluated if GST-RII could bind endogenous cyclin B2 and Cdc2 from lysates of a monocytic cell line, THP1. This cell line was chosen because it expressed surface TGFb receptor and TGFb, at 20 ng/ ml, eectively inhibited its proliferation in vitro (data not shown). The THP1 lysates were applied to GST-RII fusion protein, and bound proteins were Western blotted with speci®c anti-B1, anti-B2 or anti-Cdc2. Cyclin B2 and its associated Cdc2 from untreated THP-1 cells interacted weakly with GST-RII ( Figure  3a) , mimicking earlier in vitro data on the low anity of full-length cyclin B2 for RII. In light of the high homology between cyclin B1 and B2 and their common association with Cdc2, binding of endogenous cyclin Bl to TGFb RII was also analysed. Interestingly, cyclin Bl from untreated THP-1 cells also bound GST-RII moderately. Binding of both cellular cyclin Bl and B2 markedly rose after 5 min activation with TGFb, suggesting that TGFb can overcome the negative regulatory domain of cyclin B. Cdc2 association with GST-RII at 60 min after TGFb treatment (bottom panel, lane 6) could be due to the presence of cyclin B1 at the same time (middle panel, lane 6). To con®rm this, we demonstrated that GST-B1 fusion protein could bind endogenous TGFb RII from TGFb-treated THP-1 cells (data not shown). We next sought to determine if TGFb-RII could be found linked to cyclin B2 endogenously in whole cell lysates from TGFbtreated THP-1 cells. Figure 3c shows that cyclin B2 immunoprecipitates contained TGFb RII within 15 min of treatment of THP-1 cells with TGFb, and this association declined at 60 min. Western blot analysis with anti-TGFb RII of whole cell lysates (W) was included as a positive control, and normal rabbit serum (NRS) immunoprecipitates, run as a negative control, showed no band.
A slower migrating Cdc2 band was detected from TGFb-treated THP-1 cells in the RII complex, upon longer exposure of the same ®lm in Figure 3a , which suggested phosphorylation of Cdc2 (Figure 3b ). To con®rm this, an in vitro kinase assay was performed using lysate proteins from TGFb-treated THP1 cells bound to GST-B2T. In the presence of [g-32 P]ATP, phosphorylation of cellular Cdc2 bound to the TGFbRII-cyclin B2T complex was signi®cantly enhanced after the TGFb receptor was triggered by TGFb (Figure 4a, top panel) . Peak phosphorylation was observed after 15 min of TGFb treatment. Prior immunodepletion of the cell lysates with anti-RII antibody abolished Cdc2 phosphorylation. Western blotting of the GST-B2T bound protein on a parallel gel demonstrated that comparable levels of cellular Cdc2 bound to GST-B2T at all the time points tested (Figure 4a, bottom panel) . Alternatively, a completely Figure 4 Functional signi®cance of the interaction of cyclin B with RII and induction of Cdc2 phosphorylation in THP-1 cells by TGFb. (a) Increased Cdc2 phosphorylation by TGFb treatment. Lysates from THP-1 cells, untreated or treated with 10 ng/ml of TGFb, were immunoprecipitated with normal rabbit serum (lanes 1 ± 6) or anti-TGFb RII (lane 7). The immunoprecipitated proteins were incubated with GST alone or GST-cyclin B2T. The absorbed proteins were divided into two aliquots, and one was used in an in vitro kinase assay (top panel) which was carried out in 25 ml of 50 mM Tris-HCl (pH 7.4), 10 mM MgCl 2 , 1 mM DTT, 50 mM ATP and 20 mCi of [g-32 P]ATP (Amershan) at 308C for 30 min. The reaction was stopped with an equal volume of 26SDS sample loading buer. The sample was then boiled for 5 min, and analysed by a 10% SDS ± PAGE gel. The second aliquot of immunoprecipitates was blotted with anti-Cdc2 (bottom panel). (b) THP-1 cells were labeled with orthophosphate for 4 h, treated with (+) or without (7) TGFb for 15 min and then lysed. P-labeled Cdc2 from (b) was cut and subjected to phosphoamino acid analysis using two-dimensional electrophoresis on thin layer cellulose plates. THP-1 cells were labeled with orthophosphate as described (Ausubel et al., 1995) and lysed with NP-40 lysing buer. The THP-1 lysates were immunoprecipitated with anti-Cdc2 and separated on a 10% SDS ± PAGE gel.
32 P-labeled Cdc2 bands were identi®ed by lining up the exposure with the membrane and excised. The Cdc2 protein was hydrolyzed out of the membrane in 100 ml of 6 N HCl for 1 h at 1108C, lyophilized and dissolved in 6 ml pH 1.9 running buer containing 100 mg/ml of each unlabeled threonine, serine and tyrosine. Samples were spotted onto a thin layer cellulose plate, and electrophoresis was run in two dimensions. The plate was dried and stained with ninhydrin (0.25% in acetone) to visualize marker phosphoamino acids, and expose to ®lm. The positions of co-electrophoresed unlabeled phosphoamino acids are indicated (T, threonine, S, serine; Y, tyrosine). (d) Kinetic study of the eect of TGFb on Cdc2 kinase activity in THP-1 cells. THP-1 cells (2610) were incubated with TGFb, immunoprecipitated with anti-Cdc2, and subjected to an in vitro H1 histone kinase assay in vivo system was used to analyse TGFb mediated phosphorylation of Cdc2 that became associated with TGFb RII. For this purpose, TGFb-treated or -un-treated 32 P-labeled THP-1 lysates were immunoprecipitated with anti-Cdc2. Upon TGFb treatment, Cdc2 phosphorylation was signi®cantly increased (Figure 4b ). Because Tyr and Thr are the two major amino acids phosphorylated in Cdc2, we next examined which amino acid was being aected in Cdc2, upon association with TGFb RII. Western blot analysis with anti-phosphotyrosine did not detect any change in Tyr phosphorylation of Cdc2 between TGFb treated and untreated THP1 cells (data not shown). Further phosphoamino acid analysis with 32 P-labeled Cdc2 showed that only Thr phosphorylation was signi®cantly enhanced by TGFb treatment ( Figure  4c ). Thr-14 and Thr-161 phosphorylation are associated with Cdc2 inactivation and activation respectively. To understand whether TGFb induction of increased Cdc2 phosphorylation is associated with its functional modi®cation, Cdc2 immunoprecipitates of TGFb-treated THP-1 cell lysates were assayed for histone H1 kinase activity. High levels of kinase activity detected in Cdc2 in untreated cells were progressively lost after TGFb treatment, and 90% inhibition was achieved by 30 min (Figure 4d ).
Key events in the cell cycle are regulated by a speci®c order of Cdks, which require binding to targeted cyclins for kinase function. Cdc2 is positively regulated by cyclin B (Pines and Hunter, 1989; Ghiara et al., 1991; Surana et al., 1991) . The binding of cyclin B to Cdc2 induces phosphorylation of the complex, which leads to its activation at the G2 to M transition (Enoch and Nurse, 1990; Gould et al., 1991) . Its activity is regulated by reversible phosphorylation of multiple sites in Cdc2, with Thr-161 phosphorylation, and dephosphorylation of Thr-14 and Tyr-15 driving Cdc2 kinase activity at the G2/M transition. On the other hand, phosphorylation of Tyr-15 and Thr-14 blocks Cdc2 kinase activity and prevents the cell from entering M phase (Lock and Wickramasinghe, 1994; Clarke, 1994) . It is well-known that TGFb causes cell cycle arrest at the G1/S phase but reports, thus far, point to inactivation of Cdk2 kinase function and correlative increase in p21 waf nuclear accumulation. Our ®nding indicates that TGFb utilizes another pathway to arrest cells at the G1/S phase by inactivating cyclin B/Cdc2 that is required for exiting from the G1/S and entering the G2/M phase. By using yeast two-hybrid systems, several TGFb R interacting proteins that bind either TGFb RI or RII have been reported. Among these proteins, immunophilin FKBP12 and p21 ras farnesyltransferase a subunit interacted with TGFb RI and both were released upon TGFb activation (Wang et al., 1994 (Wang et al., , 1996 . TRIP-1, a WD-domain containing protein, interacted speci®cally with RII and was phosphorylated on both Ser and Thr by the receptor kinase (Chen et al., 1995) . Questions on how these interactions might aect cell growth or arrest, however, were not addressed. Our novel ®nding of the association of cyclin B2 and its companion, Cdc2, with TGFb RII, which is rapidly upregulated upon receptor triggering, strongly suggests that cyclin B2/Cdc2 may play a key role in TGFb-mediated cell cycle control.
Phosphorylation of Cdc2 on Thr-14 and Tyr-15 inhibits the enzyme activity and prevents premature initiation of mitosis. Wee1 has been identi®ed as the kinase that phosphorylates Cdc2 on Tyr-15 but not Thr-14 in various organisms (Parker and PiwnicaWorms, 1992; McGowan and Russell, 1995) . Recently, a membrane-associated inhibitory kinase, Myt1, that phosphorylates Cdc2 on both Thr-14 and Tyr-15 has been found in Xenopus (Mueller et al., 1995) . In this study, Thr phosphorylation of Cdc2 upon association with TGFb RII after TGFb treatment provides another mechanism by which Cdc2 can be inactivated, and this mechanism may account, at least partly, for the growth inhibitory eect of TGFb.
In conclusion, we have identi®ed that cyclin B associates with TGFbR II, resulting in attracting Cdc2 onto this receptor complex. Upon receptor triggering, Cdc2 becomes phosphorylated, accompanied by functional inactivation. Thus, a unique pathway in TGFb R signaling utilizes cyclin B as an adaptor protein for the interaction and phosphorylation of Cdc2 by the TGFb RII complex, which leads to Cdc2 inactivation and cell cycle arrest by preventing the cells from escaping from G1/S phase and entering G2/M phase.
